NCT04530981View on ClinicalTrials.gov

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

November 16, 2023

Study Completion Date

July 29, 2024

Conditions
GIST - Gastrointestinal Stromal Tumor
Interventions
DRUG

Ripretinib

Oral KIT/PDGFRA kinase inhibitor

DRUG

Repaglinide

Oral antihyperglycemic agent

Trial Locations (3)

32224

Mayo Clinic Florida, Jacksonville

33136

Sylvester Comprehensive Cancer Center, Miami

97239

Oregon Health & Science University, Portland

Sponsors
All Listed Sponsors
lead

Deciphera Pharmaceuticals, LLC

INDUSTRY

NCT04530981 - A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST | Biotech Hunter | Biotech Hunter